Results 211 to 220 of about 788,644 (353)

Precision detection of recent HIV infections using high-throughput genomic incidence assay. [PDF]

Microbiol Spectr, 2023
Faraci G, Park SY, Love TMT, Dubé MP, Lee HY.   +4 more
europepmc   +1 more source

Safety, Pharmacokinetics, and Dose Recommendations for Nirmatrelvir/Ritonavir in Individuals with Mild to Moderate COVID‐19 and Severe Renal Impairment

Clinical Pharmacology &Therapeutics, EarlyView.
Patients with severe renal impairment and COVID‐19 are at high risk for severe disease and death. Nirmatrelvir/ritonavir, an antiviral therapy for COVID‐19, is eliminated by renal excretion and can accumulate in patients with severe renal impairment.
Jacqueline Gerhart, Candace R. Bramson, Michelle Goulding, Haihong Shi, Olayide Oladoyinbo, Phylinda L. S. Chan, Sunring Chime, Jennifer Hammond   +7 more
wiley   +1 more source

Recent HIV Infections in Italy: Data from the HIV National Surveillance System, 2012-2023. [PDF]

Pathogens
Suligoi B, Regine V, Pugliese L, Galli C.   +3 more
europepmc   +1 more source

Prevalence and Impact of HIV Infections in Patients with Rheumatic Heart Disease: A Systematic Review and Meta-Analysis. [PDF]

Glob Heart, 2023
Lumngwena EN, Mokaila D, Aremu O, Katoto PD, Blackburn J, Zilla P, Wiysonge CS, Ntusi N.   +7 more
europepmc   +1 more source

Supplementary Table 1 from HIV Infection and Survival of Lymphoma Patients in the Era of Highly Active Antiretroviral Therapy

, 2023
Xuesong Han, Ahmedin Jemal, Erin Hulland, Edgar P. Simard, Loretta J. Nastoupil, Elizabeth Ward, Christopher R. Flowers   +6 more
openalex   +1 more source

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study

Clinical Pharmacology &Therapeutics, EarlyView.
AGILE (NCT04746183) is a Phase Ib/IIa platform, evaluating candidates to treat COVID‐19. Candidate Specific Trial 6 evaluated the safety and optimal dose of a novel intravenous formulation of favipiravir in a dose‐escalating, open‐label, randomized, controlled, Bayesian adaptive Phase Ib trial.
Tim Rowland, Richard FitzGerald, Elizabeth Challenger, Laura Dickinson, Laura J. Else, Lauren Walker, Colin Hale, Victoria Shaw, Callum Kelly, Rebecca Lyon, Jennifer Gibney, Karim Dhamani, Margaret Irwin, Yvanne Enever, Michelle Tetlow, William Wood, Helen Reynolds, Justin Chiong, Orod Osanlou, Henry Pertinez, Katie Bullock, William Greenhalf, Andrew Owen, David G. Lalloo, Michael Jacobs, Julian A. Hiscox, Thomas Jaki, Pavel Mozgunov, Geoffrey Saunders, Gareth Griffiths, Saye H. Khoo, Thomas E. Fletcher, on behalf of the AGILE CST‐6 Study Group, Shazaad Ahmad, Christopher J. Edwards, Lesley Dry, Georgie McKenzie, Aleksandra Ros, Michael Stackpoole, Laura Bradley, Karen Jennings‐Wilding, Nicholas Paton, Fred Hayden, Janet Darbyshire, Amy Lucas, Ulrika Lorch, Andrew Freedman, Richard Knight, Steven Julious   +48 more
wiley   +1 more source

The Meandrous Route of Rilpivirine in the Search for the Miraculous Drug to Treat HIV Infections. [PDF]

Viruses
De Clercq E.
europepmc   +1 more source

Kinetics of TTV Loads in Peripheral Blood Mononuclear Cells of Early Treated Acute HIV Infections. [PDF]

Viruses, 2023
Abbate I, Rozera G, Cimini E, Carletti F, Tartaglia E, Rubino M, Pittalis S, Esvan R, Gagliardini R, Mondi A, Mazzotta V, Camici M, Girardi E, Vaia F, Puro V, Antinori A, Maggi F.   +16 more
europepmc   +1 more source

Molecular study of hepatitis B virus infection in HIV-infected treatment-naive patients in Goiânia-Goiás

, 2013
Marina Pereira Ybarra Martins de Oliveira
openalex   +1 more source

SC-38 High rates of anal polyomaviruses and HPV co-infection among people living with HIV [PDF]

Matteo Fracella, Simone Passerini, Giulia Bugani, Francesca Frasca, Alessandra D’Auria, Eleonora Coratti, Letizia Santinelli, Domenico Benvenuto, EN Cavallari, Claudio Maria Mastroianni, Guido Antonelli, Alessandra Pierangeli, Gabriele d’Ettorre, Valeria Pietropaolo, Carolina Scagnolari   +14 more
openalex   +1 more source